Report
Peter Thilo Hasler

Markteintritt in Großbritannien

Nach der Erteilung der Großhandelserlaubnis durch die britische Medicines & Healthcare Products Regulatory Agen­cy (MHRA) und der Empfehlung durch das National Institute for Health and Care Excellence (NICE) sind in den kommenden Wochen die ersten Behandlungen mit Spherox in einem europäischen Land außerhalb Deutschlands zu erwarten. Bemerkenswert dabei ist u. E. die Konsequenz, mit der das CO.DON-Management den europaweiten Markteintritt seines Gelenkknorpelprodukts nach der Zulassung durch die Europäische Arzneimittelagentur (EMA) Schritt für Schritt umsetzt. Nicht zuletzt wurden bislang sämtliche Versprechungen bezüglich des EU-weiten Markteintritts vollumfänglich und zudem vorzeitig erfüllt. Dementsprechend bestätigen wir unser Kursziel von EUR 12,50 je Aktie und bekräftigen angesichts einer von uns erwarteten mittelfristigen Kursentwicklung von 32,7% auch unser Buy-Rating für die Aktien der CO.DON AG.

Underlying
co.don AG

Co.don AG is a Germany-based company that is active in the tissue engineering and regenerative medicine industry. The Company manufactures cell-based biological drugs for the use in orthopedic and neurosurgical applications. Its products are used for the treatment of focal particular cartilage defects, lumbar disc herniation, non-union fractures and dental disorders. Those include co don chondrotransplant, which is used for cartilage treatment, particularly in the knee area; co don chondrosphere, which is a three-dimensional articular cartilage cultivated outside of the body; co don chondrotransplant DISC, for the regeneration of intervertebral discs, and co don osteotransplant DENT, which is an autologous bone cell transplant for dental applications. The Company is active domestically and in other European countries.

Provider
Sphene Capital GmbH
Sphene Capital GmbH

Founded in 2010, Sphene Capital is a German based pure-play research house offering state-of-the-art research and evaluation services to European small- and mid-caps by avoiding typical conflict of interests of traditional investment banks.

As a general rule, analysts of Sphene Capital strive to understand companies better than any other analyst or investor before publishing their initiation reports. Therefore, the comprehensive initiation research reports comprise of 50-80 pages, including an extensive analysis of the value chain of the IPO candidate, its unique selling proposition, an elaborate analysis of suppliers and clients, a thorough SWOT analysis, a commercial due diligence (i. e. market and competitive analysis), an integrated financial forecast model and a profound company valuation (both DCF methodology and peer group multiples). Before publication, each of Sphene Capital’s research report will be double-checked by a fellow research colleague (“Four-eyes-principle”), ensuring highest quality and avoiding careless mistakes.

After initiation of research coverage, Sphene Capital publishes regular updates of 12-30 pages following relevant news flow from the issuer or major peers, f. ex. after acquisitions or after publication of quarterly results.

Due to Sphene Capital’s extensive experience in equity and bond research, the team has established longstanding contacts to all relevant market players, i. e. institutional investors, family offices and high net-worth individuals as well as journalists. To each of these groups, Sphene Capital’s research analysts have regular contacts during analyst and management roadshows or via daily phone calls. Finally, analysts publish articles in selected stock markets magazines and websites in which the analysts help issuers to improve their popularity on the German capital markets.

Analysts
Peter Thilo Hasler

Other Reports on these Companies
Other Reports from Sphene Capital GmbH

ResearchPool Subscriptions

Get the most out of your insights

Get in touch